Virbac SA - Asset Resilience Ratio

Latest as of December 2024: 0.23%

Virbac SA (VIRP) has an Asset Resilience Ratio of 0.23% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Virbac SA total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

€4.31 Million

≈ $5.04 Million USD Cash + Short-term Investments

Total Assets

€1.90 Billion

≈ $2.22 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2011–2024)

This chart shows how Virbac SA's Asset Resilience Ratio has changed over time. See VIRP total equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Virbac SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Virbac SA.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€4.31 Million	0.23%
Total Liquid Assets	€4.31 Million	0.23%

Asset Resilience Insights

Limited Liquidity: Virbac SA maintains only 0.23% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Virbac SA Industry Peers by Asset Resilience Ratio

Compare Virbac SA's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Pfizer Inc SA:PFIZ34	Drug Manufacturers - General	7.18%
CSPC Pharmaceutical Group Limited F:CVG	Drug Manufacturers - General	4.64%
Aurora Optoelectronics Co Ltd SHG:600666	Drug Manufacturers - General	5.89%
Shandong Keyuan Pharmaceutical Co. Ltd. A SHE:301281	Drug Manufacturers - General	6.44%
Dimed S.A. Distribuidora de Medicamentos SA:PNVL3	Drug Manufacturers - General	10.10%
Pfizer Inc NYSE:PFE	Drug Manufacturers - General	7.18%
Merck & Company Inc NYSE:MRK	Drug Manufacturers - General	14.06%
Firebrick Pharma Ltd AU:FRE	Drug Manufacturers - General	0.29%

Annual Asset Resilience Ratio for Virbac SA (2011–2024)

The table below shows the annual Asset Resilience Ratio data for Virbac SA.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	0.23%	€4.31 Million ≈ $5.04 Million	€1.85 Billion ≈ $2.16 Billion	+0.06pp
2023-12-31	0.17%	€2.50 Million ≈ $2.92 Million	€1.46 Billion ≈ $1.70 Billion	-0.01pp
2022-12-31	0.18%	€2.49 Million ≈ $2.91 Million	€1.36 Billion ≈ $1.59 Billion	+0.04pp
2021-12-31	0.15%	€1.78 Million ≈ $2.08 Million	€1.22 Billion ≈ $1.43 Billion	-0.52pp
2020-12-31	0.67%	€7.39 Million ≈ $8.64 Million	€1.11 Billion ≈ $1.30 Billion	+0.64pp
2019-12-31	0.03%	€342.00K ≈ $399.83K	€1.32 Billion ≈ $1.55 Billion	-0.03pp
2018-12-31	0.06%	€739.00K ≈ $863.97K	€1.27 Billion ≈ $1.49 Billion	-0.05pp
2017-12-31	0.11%	€1.34 Million ≈ $1.57 Million	€1.28 Billion ≈ $1.49 Billion	+0.02pp
2013-12-31	0.08%	€735.00K ≈ $859.29K	€896.23 Million ≈ $1.05 Billion	-0.11pp
2011-12-31	0.19%	€1.14 Million ≈ $1.34 Million	€588.63 Million ≈ $688.18 Million	--

pp = percentage points

About Virbac SA

PA:VIRP France Drug Manufacturers - General

Market Cap

$3.64 Billion

€3.11 Billion EUR

Market Cap Rank

#4918 Global

#80 in France

Share Price

€371.50

Change (1 day)

+2.34%

52-Week Range

€304.75 - €384.00

All Time High

€437.64